Last reviewed · How we verify
NCT07056478
RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients
Phase 3 trial testing Denosumab (Prolia) in Sarcopenia in Elderly in 130 participants. Not yet recruiting.
1 January 2028
Quick facts
| Lead sponsor | Prince of Wales Hospital, Shatin, Hong Kong |
|---|---|
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 130 |
| Start date | 1 January 2026 |
| Primary completion | 1 January 2028 |
| Estimated completion | 1 January 2030 |
| Sites | 1 location across China |
Drugs / interventions tested
- Denosumab (Prolia) — full drug profile →
- Zoledronic acide (Aclasta) — full drug profile →
Conditions studied
- Sarcopenia in Elderly — all drugs for Sarcopenia in Elderly →
Sponsor
Prince of Wales Hospital, Shatin, Hong Kong
Who can join
65 and older, any sex, with Sarcopenia in Elderly. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to conduct a pragmatic, randomized, double-blind, active-controlled trial to assess the efficacy of receptor activator of nuclear factor-kB ligand (RANKL) inhibition in the treatment of sarcopenia in hip fractures.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07056478
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Denosumab (Prolia)
Trials testing the same drug.
- NCT06720350 — Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility · Phase 4 · not yet recruiting
- NCT03029442 — The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury · Phase 4 · terminated
Other recruiting trials for Sarcopenia in Elderly
Currently open trials in the same condition.
- NCT06811324 — Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults · Phase 2 · recruiting
- NCT07412379 — Predictive Factors for Functional and Quality of Life Decline in Patients >65 Years With a Gastrointestinal Tract Cancer · recruiting
- NCT07322653 — The Effects of MediDrink Platinum+ and Fava Bean Protein Hydrolysate on Fitness in an Aged Population · NA · recruiting
- NCT06853275 — The Influence of Movement Velocity Biofeedback on Muscle Activation and Self Perception in Older Adults With Sarcopenia · NA · recruiting
- NCT07124338 — Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy, a Feasibili · NA · active not recruiting
Other Prince of Wales Hospital, Shatin, Hong Kong trials
Trials by the same sponsor.
- NCT07455539 — LAmbre™ II Left Atrial Appendage Occluder and Occluder Delivery System for Patients With Non-Valvular Atrial Fibrillatio · NA · not yet recruiting
- NCT07323238 — Hong Kong Cardiogenic Shock Initiative · not yet recruiting
- NCT07516145 — Robotic Transjugular Transcatheter Tricuspid Valve Replacement · NA · recruiting
- NCT07257614 — Left Atrial Appendage Occlusion in Dialysis Patients With Atrial Fibrillation: A Multicentre Pilot Study · not yet recruiting
- NCT07296016 — The Asia-Pacific Mitral & Tricuspid Valve-in-Valve/Valve-in-Ring Registry · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07056478 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prince of Wales Hospital, Shatin, Hong Kong
- Last refreshed: 9 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07056478.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing